ID 204898441 · FY 2018–2024 · 7 years
კომპანიის ძირითად საქმიანობას წარმოადგენს მედიკამენტების იმპორტი და რეალიზაცია.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 51.8% | 46.1% | 50.4% | 49.0% | 56.1% | 57.0% | 49.2% |
| EBITDA Margin | 31.6% | 21.5% | 31.3% | 23.0% | 37.5% | 24.3% | 17.7% |
| EBITDAR | 1,693 | 1,229 | 2,248 | 1,999 | 3,534 | 1,977 | 1,528 |
| EBITDAR Margin | 32.7% | 23.2% | 32.8% | 24.2% | 38.5% | 25.2% | 19.0% |
| EBIT Margin | 31.6% | 21.5% | 31.3% | 23.0% | 37.5% | 24.3% | 17.7% |
| Net Profit Margin | 31.0% | 21.5% | 28.2% | 19.6% | 34.2% | 19.0% | 14.0% |
| Operating Expense % of Sales | 20.2% | 24.6% | 19.1% | 26.1% | 18.7% | 32.7% | 31.5% |
| Returns | |||||||
| Return on Assets (ROA) | 39.5% | 22.3% | 33.9% | 23.1% | 41.3% | 21.7% | 16.0% |
| Return on Equity (ROE) | 45.9% | 32.7% | 44.6% | 32.2% | 46.8% | 22.4% | 17.9% |
| ROIC [EBIT / Invested Capital] | 49.2% | 34.1% | 49.8% | 32.5% | 49.0% | 29.1% | 22.5% |
| Leverage & liquidity | |||||||
| Debt-to-Assets | 7.2% | 6.5% | 6.6% | 16.5% | 4.9% | 0.0% | 2.1% |
| Debt-to-Equity | 0.08x | 0.10x | 0.09x | 0.23x | 0.06x | 0.00x | 0.02x |
| Debt-to-EBITDA | 0.18x | 0.29x | 0.17x | 0.61x | 0.11x | 0.00x | 0.10x |
| Equity-to-Assets | 86.1% | 68.4% | 76.1% | 71.6% | 88.1% | 96.8% | 89.3% |
| Net Debt | -167 | -149 | -30 | 809 | 305 | -121 | 40 |
| Cash & Equivalents | 461 | 482 | 405 | 351 | 66 | 121 | 109 |
| Total Debt | 294 | 333 | 374 | 1,159 | 371 | N/A | 150 |
| Efficiency & working capital | |||||||
| Inventory Turnover | N/A | 1.27x | 1.49x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 286.5 | 245.0 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 4.28x | 3.66x | 3.48x | 4.06x | 2.66x | 2.60x | 2.78x |
| Days Sales Outstanding (DSO) | 85.2 | 99.7 | 104.9 | 89.9 | 137.1 | 140.2 | 131.4 |
| Payables Turnover | 9.42x | 2.25x | 3.45x | 5.06x | 7.52x | 15.27x | 6.70x |
| Days Payable Outstanding (DPO) | 38.7 | 162.0 | 105.9 | 72.1 | 48.6 | 23.9 | 54.5 |
| Cash Conversion Cycle | 46.5 days | 224.1 days | 244.1 days | 17.8 days | 88.5 days | 116.3 days | 76.9 days |
| Asset Turnover | 1.27x | 1.04x | 1.20x | 1.18x | 1.21x | 1.14x | 1.14x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | 1,464 | 1,130 | 927 | 242 | 1,928 | 2,056 | 1,304 |
| Free Cash Flow (OCF − Capex proxy) | 187 | 1,130 | 927 | 156 | 1,928 | 1,967 | 1,283 |
| Cash Conversion (OCF / EBITDA) | 89.3% | 99.2% | 43.2% | 12.8% | 56.0% | 108.2% | 91.5% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).